In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.

Market volatility, persistently high valuations, inflation and interest rates are among the issues sidetracking broader M&A, experts say.

Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.

The path for developing a variant-adapted COVID-19 vaccine remains uncertain, but the company expects to have more clarity following an FDA advisory committee meeting in June.

Enhertu secured US FDA approval as a second-line treatment in HER2-positive breast cancer, where it is poised to become the new standard of care.